Funding History

As Principal Investigator

• “Is ERBB4 a Driver of BRAF WT Melanomas: Diversity Administrative Supplement” National Institutes of Health/National Cancer Institute; R15CA280767-01A1S1; David J. Riese II, PI;  Markelle Scott, Trainee; 08/01/24 – 12/31/26; $20,349 total costs (total direct costs = $13,300)

• “Is ERBB4 a Driver of BRAF WT Melanomas” National Institutes of Health/National Cancer Institute; R15CA280767-01A1; David J. Riese II, PI;  Robert "Rusty" Arnold, Auburn University, co-investigator; 01/01/24 – 12/31/26; $450,826 total costs (total direct costs = $300,000)

• "Targeted Melanoma Therapy: Identification of ERBB4 Melanoma Driver Mutants"; Auburn University IGP; David J. Riese II, PI; 06/01/20 - 05/31/22; $50,000 total direct costs (Riese lab direct costs = $50,000)

• “Validation of Canine Models for Human Breast Cancer”; Auburn University IGP; David J. Riese II, PI; Curtis Bird, COVM, co-PI; 01/01/11 – 12/31/12; $70,125 total direct costs (Riese lab direct costs = $35,062)

• “Regulation of ErbB4 Signaling by Neuregulin Isoforms” National Institutes of Health/National Cancer Institute; R01CA114209; David J. Riese II, PI;  Mark A. Lemmon, UPenn, subcontractor; 08/01/06 – 07/31/12; $1,241,777 total costs (Riese lab direct costs = $607,980)

• “Instructional Equipment Grant”; Purdue University School of Pharmacy; David J. Riese II, PI; 06/01/10 – 12/31/10; $6,400 total costs

• “Instructional Equipment Grant”; Purdue University School of Pharmacy; David J. Riese II, PI; 01/01/09 – 12/31/09; $4,000 total costs

• “Synthesis and Evaluation of Targeted Cancer Chemotherapeutic Nanotubes”; Purdue University School of Pharmacy; David J. Riese II, PI; Donald Bergstrom, co-PI; 01/01/08 – 12/31/08; $75,000 total costs (Riese lab direct costs = $25,000)

• “Identification of a Potential Mechanism by Which Parkinson's Disease Patients Exhibit an Elevated Risk of Breast Cancer”; Purdue University Showalter Trust; David J. Riese II, PI;  Val J. Watts, co-PI; 07/01/05 – 12/31/06; $62,500 total direct costs

• “Regulation of Prostate Tumor Cell Line Proliferation and Tumorigenicity by the ErbB4 Receptor Tyrosine Kinase”; USAMRMC Prostate Cancer Research Program; DAMD17-02-1-0130/PC010077; David J. Riese II, PI; 02/01/02 – 01/31/05; $225,000 total direct costs

• “Tumor Imaging Agents Directed Against ErbB2”; National Institutes of Health/National Cancer Institute; R21CA089274; David J. Riese II, PI; 07/01/01 – 06/30/04; $200,000 total direct costs

• “Functional Analysis of the ErbB4 Receptor Tyrosine Kinase”; USAMRMC Breast Cancer Research Program; DAMD17-00-1-0415/BC990790; David J. Riese II, PI; 07/01/00 – 06/30/04; $ 132,000 total direct costs

• “Functional Analysis of the ErbB4 Receptor Tyrosine Kinase”; USAMRMC Breast Cancer Research Program; DAMD17-00-1-0416/BC990107; David J. Riese II, PI; 07/01/00 – 06/30/03; $216,000 total direct costs 

• “Inhibition of Breast Tumor Cell Line Proliferation, Motility, and Invasiveness”; National Institutes of Health/National Cancer Institute; R21CA080770; David J. Riese II, PI; 04/01/99 – 03/31/01; $150,000 total direct costs

• “Studies of the ErbB4 Receptor Tyrosine Kinase”; Showalter Trust; David J. Riese II, PI; 07/01/98 – 06/30/99; $45,200 total direct costs

As Co-investigator (selected)

• “Graduate Assistance in the Areas of National Need (GAANN): Fellowships in Biological and Pharmaceutical Engineering”; US Department of Education; P200A120244; ME Byrne, AU Department of Chemical Engineering, PI; David J. Riese II, investigator/mentor; 08/01/12 – 07/31/16; $824,532 total costs (funds supported a shared GRA)

• "Cancer Center Support Grant" National Institutes of Health/National Cancer Institute; P30CA023168; Timothy Ratliff, Purdue University, PI; David J. Riese II, et al., co-PIs; 09/08/10 - 06/30/15; $ 6,407,190 total costs ($0 direct costs for Riese laboratory - this grant supported the Purdue University Center for Cancer Research - Dr. Riese is no longer affiliated with that organization)

• "LEAP Image Scanning Cytometer Shared Instrument"; National Institutes of Health; S10RR023651; James Leary, Purdue University, PI; David J. Riese II, et al., co-PIs; 01/07/10 - 01/06/11; $495,000 total costs ($0 direct costs for Riese laboratory)

• "Gefitinib-Sensitive EGF Receptor Mutants in Lung Cancer"; National Institutes of Health/National Cancer Institute; R01CA115830; Jeffrey Settleman, Massachusetts General Hospital, PI; David J. Riese II, co-PI; 06/01/05 -  04/30/10; $200,000 total direct costs for the Riese laboratory

• “Targeted Molecular Probes for Tumor Imaging”; National Institutes of Health/National Cancer Institute; R01CA094253; Henry VanBrocklin, Lawrence Berkeley National Laboratory, PI; David J. Riese II, co-PI; 09/01/02 – 08/31/06; $240,000 total direct costs for the Riese laboratory

• “A Summer Undergraduate Training Program in Breast Cancer Research”; USAMRMC Breast Cancer Research Program; DAMD17-02-1-0555/BC010171; G. Marc Loudon, Purdue University, PI; David J. Riese II, co-PI; 05/01/02 – 04/30/06; $141,000 total direct costs ($0 directly for the Riese laboratory)

• “Binding determinants of Neuregulin to the ErbB4 receptor”; National Institutes of Health/National Cancer Institute; F33CA085049; Robert P. Hammer, Louisiana State University, PI; David J. Riese II, mentor; 03/15/00 – 03/14/01; $46,000 annual direct costs (stipend for Dr. Hammer)